Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Lyden, Patrick MD *,1; Pryor, Kent E. PhD 2; Coffey, Christopher S. PhD 3; Cudkowicz, Merit MD, MSc 4; Conwit, Robin MD 5; Jadhav, Ashutosh MD, PhD 6; Sawyer, Robert N. Jr MD 7; Claassen, Jan MD 8; Adeoye, Opeolu MD 9; Song, Shlee MD 1; Hannon, Peter MD 10; Rost, Natalia S. MD, MPH 4; Hinduja, Archana MD 11; Torbey, Michel MD, MPH 11; Lee, Jin-Moo MD, PhD 12; Benesch, Curtis MD 13; Rippee, Michael MD 14; Rymer, Marilyn MD 14; Froehler, Michael T. MD, PhD 15; Clarke Haley, E. MD 16; Johnson, Mark MD 17; Yankey, Jon MS 3; Magee, Kim MS 3; Qidwai, Julie MS 3; Levy, Howard MD, PhD 18; Mark Haacke, E. PhD 19; Fawaz, Miller MS 19; Davis, Thomas P. PhD 20; Toga, Arthur W. PhD 21; Griffin, John H. PhD 22; Zlokovic, Berislav V. MD, PhD 23; the NeuroNEXT Clinical Trials Network NN104 Investigators
[Article] Annals of Neurology. 85(1):125-136, January 2019.

(Format: HTML, PDF)